J
James J. Mulé
Researcher at University of South Florida
Publications - 185
Citations - 16736
James J. Mulé is an academic researcher from University of South Florida. The author has contributed to research in topics: Immunotherapy & Immune system. The author has an hindex of 63, co-authored 172 publications receiving 15698 citations. Previous affiliations of James J. Mulé include University of Michigan & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity.
Marcin Kortylewski,Maciej Kujawski,Tianhong Wang,Sheng Wei,Shumin M. Zhang,Shari Pilon-Thomas,Guilian Niu,Heidi Kay,James J. Mulé,William G. Kerr,Richard Jove,Drew M. Pardoll,Hua Yu +12 more
TL;DR: It is shown that Stat3 is constitutively activated in diverse tumor-infiltrating immune cells, and ablating Stat3 in hematopoietic cells triggers an intrinsic immune-surveillance system that inhibits tumor growth and metastasis.
Journal ArticleDOI
Bif-1 interacts with Beclin 1 through UVRAG and regulates autophagy and tumorigenesis.
Yoshinori Takahashi,Domenico Coppola,Norimasa Matsushita,Hernani D. Cualing,Mei Sun,Yuya Sato,Chengyu Liang,Jae U. Jung,Jin Q. Cheng,James J. Mulé,W. Jack Pledger,Hong Gang Wang +11 more
TL;DR: It is demonstrated that Bif-1 interacts with Beclin 1 through ultraviolet irradiation resistance-associated gene (UVRAG) and functions as a positive mediator of the class III PI(3) kinase (PI( 3)KC3) and observed that B if-1 ablation prolongs cell survival under starvation conditions.
Journal ArticleDOI
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.
TL;DR: The adoptive transfer of lymphokine-activated killer cells to mice with established pulmonary sarcoma metastases was highly effective in reducing the number (and size) of these tumor nodules when combined with repeated injections of recombinant IL-2.
Journal ArticleDOI
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
TL;DR: It appears that the mechanism of the antitumor effect of recombinant IL-2 administered systemically is via the generation of LAK cells in vivo, although this hypothesis remains to be proven.
Journal ArticleDOI
Design and Function of a Dendrimer-Based Therapeutic Nanodevice Targeted to Tumor Cells Through the Folate Receptor
Antonio Quintana,Ewa Raczka,Lars T. Piehler,Inhan Lee,Andrzej Myc,Istvan J. Majoros,Anil K. Patri,Thommey P. Thomas,James J. Mulé,James R. Baker +9 more
TL;DR: These results demonstrate the ability to design and produce polymer-based nanodevices for the intracellular targeting of drugs, imaging agents, and other materials.